Naamidine J |
カタログ番号GC27640
One-Click Copy Product Info
|
Naamidine J is an imidazole-type alkaloids discovered in a sponge.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2227550-73-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Naamidine J is an imidazole-type alkaloids discovered in a sponge. Naamidine J inhibits inflammation by binding to the protein CSE1L (KD = 5.41 μM). Namidine J significantly inhibits the expression of pro-inflammatory factors such as TNF-α, IL-1β, and IL-6, and upregulates anti-inflammatory factors such as CD206 and Arg-1. Namidine J inhibits PD-L1 and shows antitumor activity. Namidine J significantly reduces pulmonary tissue edema, inflammatory cell infiltration and cytokine storm in mice. Namidine J can be used for the research on the immune microenvironment of acute lung injury and tumors[1][2].
Naamidine J (5 μM, 24 h) was cytotoxic to K562 cells with an IC50 of 11.3 μM, but non-toxic to macrophages and RKO cells (IC50 > 40 μM) [1][2].
Naamidine J (10 μM, 24 h) reduced PD-L1 expression in RKO cells and PDAC cells [1][3].
Naamidine J (1-5 μM, 5 h) inhibited LPS-induced inflammatory responses in RAW264.7 macrophages [2].
Naamidine J (5 μM, 5 h) inhibited CSE1L-mediated SP1 nuclear translocation in LPS-induced macrophages [2].
Naamidine J (10 μM, 24 hours) can restore the cytotoxicity of CD8+ T cells and significantly reduce the survival rate of PDAC cells (MIA-PaCa2, BxPC-3)[3].
References:
[1]. Fu PP, et al. Bioactivity-Driven Synthesis of the Marine Natural Product Naamidine J and Its Derivatives as Potential Tumor Immunological Agents by Inhibiting Programmed Death-Ligand 1. J Med Chem. 2023 Apr 27;66(8):5427-5438.
[2]. Gao CL, et al. Chemoproteomics of Marine Natural Product Naamidine J Unveils CSE1L as a Therapeutic Target in Acute Lung Injury. J Am Chem Soc. 2024 Oct 16;146(41):28384-28397.
[3]. Chen E, et al. NAT10 regulates tumor progression and immune microenvironment in pancreatic ductal adenocarcinoma via the N4-acetylated LAMB3-mediated FAK/ERK pathway. Cancer Commun (Lond). 2025 Sep;45(9):1162-1187.
Naamidine J (10-20 mg/kg, intraperitoneal injection, once daily for 3 consecutive days) significantly alleviated LPS-induced acute lung injury and pulmonary edema in mice.
Naamidine J (30 mg/kg, intraperitoneal injection, every three days for 28 days) significantly increased the proportion of CD8+ T cell subsets and decreased the proportion of CD8+ Th cell subsets in tumor-bearing mice with high NAT10 expression.
| Cas No. | 2227550-73-2 | SDF | |
| Formula | C25H27N5O5 | M.Wt | 477.51 |
| 溶解度 | DMSO : 4.55 mg/mL (9.53 mM; ultrasonic and warming and heat to 60°C) | Storage | 4°C, protect from light |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0942 mL | 10.471 mL | 20.942 mL |
| 5 mM | 418.8 μL | 2.0942 mL | 4.1884 mL |
| 10 mM | 209.4 μL | 1.0471 mL | 2.0942 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)